Chinese e-commerce conglomerate Alibaba Group's (NYSE: BABA) healthcare subsidiary Alibaba Health Information Technology (0241.HK) recently announced that it has partnered with British pharmaceutical company GlaxoSmithKline to launch a "Ruizhi-Adult Vaccination Services Program" (Ruizhi Program), which will offer online disease education and consultation and appointment-booking services.
The Ruizhi Program will initially offer only cervical cancer vaccination appointment booking services and related information and consulting services. Patients can use Alibaba Group's mobile Taobao app to check for participating healthcare service locations and can also check on vaccination information for local health service centers. In addition, users can select a time to visit a local health services center for an in-person vaccination consultation.
Currently, the program covers 14 provinces including Anhui, Fujian, Guangxi, Hainan, Henan, Heilongjiang, Jiangxi, Liaoning, Inner Mongolia, Shandong, Shaanxi, Sichuan, Yunnan, and Chongqing. By the end of the year, it expects to offer online appointment-booking services for nearly 1,000 local health service centers in hundreds of cities including Beijing, Shanghai, Guangzhou, Shenzhen, Hangzhou, Nanjing, and Wuhan.
According to a representative from GSK, the company will also cooperate with Alibaba Health in other domains including vaccinations for children and other types of vaccines. The two partners will offer preventative care information for users and O2O services such as online physician Q&A.